James Sabry adds an­oth­er weapon to Roche-Genen­tech ar­se­nal; Dai­ichi Sankyo adds ADC #6

James Sabry and Aviv Regev at Roche and Genen­tech have been rack­ing up ear­ly stage part­ner­ships, ty­ing up with ear­ly stage biotechs de­vel­op­ing every­thing from new AI en­gines to new ways of de­liv­er­ing gene ther­a­py. Now, they’ve signed on with an old­er play­er, join­ing a small mol­e­cule biotech that’s al­ready col­lab­o­rat­ed with many of the biggest names in drug de­vel­op­ment.

Genen­tech and X-Chem, a biotech that spe­cial­izes in DNA-en­cod­ed li­braries, have signed an agree­ment that will al­low the big biotech to both use their tech­nol­o­gy to find new mol­e­cules and give them an ex­clu­sive li­cense on a pre-ex­ist­ing pro­gram. De­tails for that pro­gram were undis­closed, as were up­front pay­ment and mile­stones.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA